Publication:
A database for screening and registering late onset Pompe disease in Turkey

dc.contributor.authorKAHRAMAN KOYTAK, PINAR
dc.contributor.authorsGokyigit, Munevver Celik; Ekmekci, Hakan; Durmus, Hacer; Karll, Necdet; Koseoglu, Emel; Aysal, Fikret; Kotan, Dilcan; Ali, Asuman; Koytak, Pinar Kahraman; Karasoy, Hatice; Yaman, Aylin; Sengun, Ihsan Sukru; Sayin, Refah; Tiftikcioglu, Bedile Irem; Soysal, Aysun; Tutkavul, Kemal; Bayrak, Ayse Oytun; Kisabay, Aysin; Elci, Mehmet Ali; Yayla, Vildan; Yilmaz, Ibrahim Arda; Ozdamar, Sevim Erdem; Erdogan, Cagdas; Tasdemir, Nebahat; Oflazer, Piraye Serdaroglu
dc.date.accessioned2022-03-12T22:27:53Z
dc.date.accessioned2026-01-11T11:09:26Z
dc.date.available2022-03-12T22:27:53Z
dc.date.issued2018
dc.description.abstractThe aim of this study was to search for the frequency of late onset Pompe disease (LOPD) among patients who had a myopathy with unknown diagnosis registered in the pre-diagnostic part of a novel registry for LOPD within a collaborative study of neurologists working throughout Turkey. Included in the study were 350 patients older than 18 years who have a myopathic syndrome without a proven diagnosis by serum creatine kinase (CK) levels, electrodiagnostic studies, and/or muscle pathology, and/or genetic tests for myopathies other than LOPD. Acid alpha glucosidase (GAA) in dried blood spot was measured in each patient at two different university laboratories. LOPD was confirmed by mutation analysis in patients with decreased GAA levels from either both or one of the laboratories. Pre-diagnostic data, recorded by 45 investigators from 32 centers on 350 patients revealed low GAA levels in a total of 21 patients; from both laboratories in 6 and from either one of the laboratories in 15. Among them, genetic testing proved LOPD in 3 of 6 patients and 1 of 15 patients with decreased GAA levels from both or one of the laboratories respectively. Registry was transferred to Turkish Neurological Association after completion of the study for possible future use and development. Our collaborative study enabled collection of a considerable amount of data on the registry in a short time. GAA levels by dried blood spot even from two different laboratories in the same patient may not prove LOPD. LOPD seemed to be rarer in Turkey than in Europe. (C) 2017 Elsevier B.V. All rights reserved.
dc.identifier.doi10.1016/j.nmd.2017.12.008
dc.identifier.eissn1873-2364
dc.identifier.issn0960-8966
dc.identifier.pubmed29395671
dc.identifier.urihttps://hdl.handle.net/11424/235255
dc.identifier.wosWOS:000430763800010
dc.language.isoeng
dc.publisherPERGAMON-ELSEVIER SCIENCE LTD
dc.relation.ispartofNEUROMUSCULAR DISORDERS
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectLOPD
dc.subjectRegistry
dc.subjectLimb girdle muscle weakness
dc.subjectAcid alpha glucosidase
dc.subjectGIRDLE MUSCULAR-DYSTROPHY
dc.subjectHYPERCKEMIA
dc.subjectPREVALENCE
dc.subjectMYOPATHIES
dc.subjectCOHORT
dc.titleA database for screening and registering late onset Pompe disease in Turkey
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage267
oaire.citation.issue3
oaire.citation.startPage262
oaire.citation.titleNEUROMUSCULAR DISORDERS
oaire.citation.volume28

Files